Published in
American Society of Hematology, Blood, 17(130), p. 1889-1897
DOI: 10.1182/blood-2017-05-785790
Links
Tools
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Journal article published in 2017 by
Claire N. Harrison,
Adam J. Mead,
Anesh Panchal,
Sonia Fox,
Christina Yap 
,
Emmanouela Gbandi,
Aimee Houlton,
Samah Alimam,
Joanne Ewing,
Marion Wood,
Frederick Chen,
Jason Coppell,
Nicki Panoskaltsis ,
Steven Knapper ,
Sahra Ali
and other authors.
,
Emmanouela Gbandi,
Aimee Houlton,
Samah Alimam,
Joanne Ewing,
Marion Wood,
Frederick Chen,
Jason Coppell,
Nicki Panoskaltsis ,
Steven Knapper ,
Sahra Ali
and other authors.
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points After hydroxycarbamide therapy in high-risk ET, ruxolitinib showed no improvement for complete or partial response rates compared with BAT. Ruxolitinib significantly improved some disease-related symptoms, but rates of thrombosis, hemorrhage, or transformation were not different.